Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RUA Life SciencesFRA:AOHA +5.22%48 EBIT per Share is €-0.00 as of Mar. 2026. GuruFocus rates FRA:AOHA with a GF Score™ of 48/100 and a GF Value™ of €0.14 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 685 Medical Devices & Instruments companies, RUA Life Sciences ranks better than 55.62% on this metric.
RUA Life Sciences's EBIT per Share for the
six
months ended in Mar. 2026 was €-0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.00.
During the past 3 years, the average EBIT per Share Growth Rate was 13.00% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -8.30% per year.
During the past 10 years, the average EBIT per Share Growth Rate was -7.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for RUA Life Sciences's EBIT per Share or its related term are showing as below:
FRA:AOHA'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -144.8 Med: 10.9 Max: 52
Current: 13
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of RUA Life Sciences was 52.00% per year. The lowest was -144.80% per year. And the median was 10.90% per year.
FRA:AOHA's 3-Year EBIT Growth Rate is ranked better than 55.62% of 685
companies
in the Medical Devices & Instruments industry
Industry Median: 9.6
vs FRA:AOHA: 13.00
RUA Life Sciences (FRA:AOHA) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
RUA Life Sciences EBIT per Share Related Terms
RUA Life Sciences EBIT per Share Historical Data
* Premium members only.
The historical data trend for RUA Life Sciences's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RUA Life Sciences (FRA:AOHA) has a EBIT per Share of €-0.00 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on RUA Life Sciences and its competitors. According to the industry distribution chart, RUA Life Sciences ranks #304 out of 685 companies in the Medical Devices & Instruments industry, placing it in the top 44.4%.
Is RUA Life Sciences' EBIT per Share too high?
RUA Life Sciences' current EBIT per Share is €-0.00. Based on the distribution chart, RUA Life Sciences ranks #304 out of 685 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, RUA Life Sciences has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RUA Life Sciences' EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, RUA Life Sciences ranks #304 out of 685 companies for EBIT per Share. This puts RUA Life Sciences in the upper half of its industry. The industry median EBIT per Share is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.60, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on RUA Life Sciences and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RUA Life Sciences's current EBIT per Share is €-0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RUA Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, RUA Life Sciences (FRA:AOHA) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.14, compared to a current price of €0.24 — trading 72.9% above its estimated fair value. The current EBIT per Share is €-0.00. RUA Life Sciences' overall GF Score™ is 48/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For RUA Life Sciences (FRA:AOHA), the current EBIT per Share is €-0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RUA Life Sciences (FRA:AOHA) Overvalued in 2026?
Based on GuruFocus' analysis, RUA Life Sciences stock appears to be overvalued.
The current stock price of €0.24 is trading 72.9% above its estimated GF Value™ of €0.14.
GuruFocus considers RUA Life Sciences to be Significantly Overvalued.
Key valuation signals for FRA:AOHA:
EBIT per Share: €-0.00
GF Value™: €0.14 vs. price of €0.24 (72.9% above fair value)
No single metric tells the full story. See the FRA:AOHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RUA Life Sciences PLC is engaged in the contract design and manufacture of medical devices, exploiting the value of its IP and know-how, and developing cardiovascular devices. The Biomaterials segment is a licensor of Elast-Eon polymers to the medical device industry. The Medical Devices & Components segment is an end-to-end contract developer and manufacturer of medical devices and an implantable fabric specialist, which generates maximum revenue. The Vascular segment focuses on the development and commercialisation of the Group's Elast-Eon sealed Vascular Graft products. The Structural Heart segment focuses on the development of the Group's tri-leaflet polymeric heart valves. Geographically, it operates in Europe, North America, Middle East, Asia Pacific, and Africa.
48GF Score
Get the complete analysis for FRA:AOHA
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AOHA has been successfully added to your 
